This article presents a summary of the new medications approved for generalized myasthenia gravis (gMG) since 2017. Pivotal clinical trials that led to the
myasthenia gravisneonatal Fc receptor antibodyrituximabthymectomyDespite the availability of an increasing variety of disease‐modifying therapies, the proportion of patients with generalized myasthenia gravis ( MG ) who achieved the practical treatment goal remained low at approximately 50%‐60% in our ...
Targeting B cells is an effective strategy for managing MG: Novel therapies in Myasthenia gravis The treatment of MG has evolved significantly with new therapeutic approaches targeting specific components of the immune system, offering more precision and potentially fewer side effects than traditional ...
an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG). Efgartigimod is currently under review with the U.S. Food and Drug Administration (FDA) for the treatment of gMG with
Rais et al.2023). Elranatamab has been approved for relapsed or refractory multiple myeloma after four or more prior therapies following priority review, breakthrough, and orphan drug designation (Dhillon2023b). Elranatamab is well tolerated, and the most common non-hematologic treatment-emergent ...
The US Food and Drug Administration (FDA) has approvedefgartigimod(Vyvgart, argenx), a first-in-class,targeted therapyfor adults with generalizedmyasthenia gravis(gMG) who test positive for the antiacetylcholine receptor (AChR) antibody.
Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intr...
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients' weakness, and their need for immunosuppressive drugs. The study
To date,Eque-celhas received three IND approvals from the U.S. FDA for autoimmune indications, including the treatment of Myasthenia Gravis (MG), Multiple Sclerosis (MS), and SLE/LN. In China, the product has also received two IND approvals from the National Medical Products Administration ...
New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine receptor antibody positive (AChR-Ab+) Acceptance by U.S. Food ...